ClinicalTrials.gg
RecruitingNCT05192980BIOPORTALUpdated Jul 22, 2025

SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours

An interventional study of No Intervention NA in Neuroblastoma, Ganglioneuroblastoma and Ganglioneuroma, sponsored by Institut Curie. Recruiting at 38 sites in 4 countries. Per ClinicalTrials.gov, last updated 2025-07-22.

Primary conditionGanglioneuroblastomaRegistry: NeuroblastomaReclassifiedWhy we changed it
Registry
Neuroblastoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ganglioneuroblastoma
Why
  1. The study's listed conditions name Ganglioneuroblastoma, a narrower term within Neuroblastoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Institut Curie · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Not applicable
Sex
All
01

Study summary

The SIOPEN BIOPORTAL is a prospective non-therapeutic multi-centre international study aimed at developing an international Registry linked to a Virtual Biobank for all the patients with peripheral neuroblastic tumor within countries of the SIOPEN network. The overall aim of this study is to provide a GDPR-compliant framework to collect basic clinical annotations, biological and genetic features and information about the location on biospecimens for all the patients with a peripheral neuroblastic tumor including neuroblastoma, ganglioneuroblastoma and ganglioneuroma in the SIOPEN network.

This study will support data and sample management and intensify cross-borders data and sample sharing fostering translational and clinical research. The post-hoc hypothesis formulated based on the data generated in this study will be used as statistical basis for future precision medicine programs based on improved biological characterization, patient stratification and therapeutic management.

02

Conditions studied

  • Neuroblastoma
  • Ganglioneuroblastoma
  • Ganglioneuroma

Browse trials for

03

In context

Ganglioneuroblastoma Reclassified

21 studies on the registry are indexed under Ganglioneuroblastoma; 10 are open to participants now.

This study's planned enrollment of 600 is above the median of 69 across 16 interventional studies indexed under Ganglioneuroblastoma.

Browse Ganglioneuroblastoma studies →

Lead sponsor

Institut Curie is the lead sponsor of 135 studies on the registry; 29 are open to participants now.

Compared within Ganglioneuroblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neuroblastoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

I-1. Patients with PNT: ganglioneuroma or ganglioneuroblastoma or neuroblastoma, I-2. At the time of initial diagnosis of neuroblastic tumour, or at relapse/progression if not yet registered I-3. Written patient , or parents or legal representative written informed consent and assent of the child, adolescent or young adult

Non-Inclusion Criteria:

R-1. (Adult) Patients with olfactory neuroblastoma R-2. Central nervous system (CNS) neuroblastoma (as per the WHO classification)

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Other
    Peripheral neuroblastic tumors (ganglioneuroma, ganglioneuroblastoma and neuroblastoma)

    Other: No Intervention NA

Interventions

  • OtherNo Intervention NA

    Additional blood sampling (not mandatory)

    Also known as: Bio-sampling

06

What researchers measure

Primary outcomes

  1. Rate of patients having their clinical data registered

    Registry Outcome: Rate of patients having their clinical data registered throughout their treatment and follow-up from the total of patients registered

    Time frame: 6 months

  2. Rate of patients for whom information on biological samples/material is collected

    Virtual Biobank Outcome: Rate of patients for whom information on biological samples/material collected and stored in SIOPEN is available from the total of patients registered

    Time frame: 6 months

Secondary outcomes

  1. Progression-free survival (PFS)

    Investigation of the impact of the variables currently used for assignment to risk groups and treatment stratification (MYCN Status, ALK Status, stage, age, primary tumor site) on progression-free survival (PFS) using the Kaplan-Meier method

    Time frame: 12 months

  2. Overall-survival (OS)

    Investigation of the impact of the variables currently used for assignment to risk groups and treatment stratification (MYCN Status, ALK Status, stage, age, primary tumor site) on overall-survival (OS) using the Kaplan-Meier method

    Time frame: 12 months

07

Study locations

35 of 38 sites recruiting
  • Fakultni nemocnice v Motole
    Prague, 150 06, Czechia
    Recruiting
  • CHU Amiens
    Amiens, 80054, France
    Recruiting
    • Antoine GOURMEL, MD · Principal investigator
  • Chu Angers
    Angers, 49033, France
    Recruiting
    • Stéphanie PROUST, MD · Principal investigator
  • Hôpital Jean Minjoz
    Besançon, 25030, France
    Recruiting
    • Veronique LAITHIER, MD · Principal investigator
  • Hôpital des enfants
    Bordeaux, 33076, France
    Recruiting
    • Julie TANDONNET, MD · Principal investigator
  • Chru Brest
    Brest, 29609, France
    Recruiting
    • Liana CARAUSU, MD · Principal investigator
  • CHU CAEN - Fédération de cancérologie - niveau 21
    Caen, 14033, France
    Recruiting
    • Damien BODET, MD · Principal investigator
  • CHU D'Estaing de CLERMONT FERRAND
    Clermont-Ferrand, 63003, France
    Recruiting
    • Justyna KANOLD, MD · Principal investigator
  • DIJON Hôpital d'enfants
    Dijon, 21079, France
    Recruiting
    • Claire BRIANDET, MD · Principal investigator
  • Chu Grenoble
    Grenoble, 38045, France
    Recruiting
    • Cécile PERRET, MD · Principal investigator
  • Centre Oscar Lambret
    Lille, 59020, France
    Recruiting
    • Anne-Sophie DEFACHELLES, MD · Principal investigator
  • Centre Léon Bérard
    Lyon, 69373, France
    Recruiting
    • Benoît DUMONT, MD · Principal investigator
  • Hôpital d'Enfants de la Timone
    Marseille, 13385, France
    Recruiting
    • Carole COZE, MD · Principal investigator
  • Hôpital Arnaud de Villeneuve
    Montpellier, 34295, France
    Recruiting
    • Tasnime AKBARALY, MD · Principal investigator
  • Chr Nantes
    Nantes, 44093, France
    Recruiting
    • Estelle THEBAUD, MD · Principal investigator
  • CHU NICE
    Nice, 06202, France
    Recruiting
    • Joy BENADIBA, MD · Principal investigator
  • Institut Curie
    Paris, 750248, France
    Recruiting
  • Hôpital Armand Trousseau
    Paris, 75571, France
    Recruiting
    • Arnaud PETIT, MD · Principal investigator
  • Hôpital Jean Bernard
    Poitiers, 86021, France
    Not yet recruiting
    • Chrystelle DUPRAZ, MD · Principal investigator
  • Chu Reims
    Reims, 51092, France
    Recruiting
    • Claire PLUCHART, MD · Principal investigator
  • Chu Hopital Sud
    Rennes, 35056, France
    Recruiting
    • Sophie TAQUE, MD · Principal investigator
  • Hôpital Charles NICOLLE
    Rouen, 76031, France
    Recruiting
    • Aude MARIE CARDINE, MD · Principal investigator
  • Hôpital Nord
    Saint-Etienne, 42055, France
    Not yet recruiting
    • Claire BERGER, MD · Principal investigator
  • Hôpital Hautepierre-CHU Strasbourg
    Strasbourg, 67098, France
    Recruiting
    • Sarah JANNIER, MD · Principal investigator
  • Hôpital des Enfants
    Toulouse, 70034, France
    Recruiting
    • Marion GAMBART, MD · Principal investigator
  • Hôpital Clocheville
    Tours, 37044, France
    Not yet recruiting
    • Julien LEJEUNE, MD · Principal investigator
  • CHU NANCY- Hôpital d'Enfants
    Vandœuvre-lès-Nancy, 54500, France
    Recruiting
    • Ludovic MANSUY, MD · Principal investigator
  • Institut Gustave Roussy
    Villejuif, 94800, France
    Recruiting
    • Claudia PASQUALINI, MD · Principal investigator
  • Oslo Universitetssykehus
    Oslo, 0424, Norway
    Recruiting
    • Kirsten Brunsvig Jarvis, MD · Contactkirjar@ous-hf.no
    • Kirsten Brunsvig Jarvis, MD · Principal investigator
  • Kantonsspital Aarau AG
    Aarau, 5001, Switzerland
    Recruiting
  • Universitäts-Kinderspital beider Basel UKBB
    Basel, 4056, Switzerland
    Recruiting
  • Ospedale San Giovanni
    Bellinzona, 6500, Switzerland
    Recruiting
  • Inselspital Bern
    Bern, 3010, Switzerland
    Recruiting
  • HUG Hôpitaux Universitaires Genève
    Geneva, 1205, Switzerland
    Recruiting
    • Fabienne Gumy-Pause, MD · Contact
    • Fabienne Gumy-Pause, MD · Principal investigator
  • CHUV, Centre hospitalier universitaire vaudois
    Lausanne, 1011, Switzerland
    Recruiting
  • Kinderspital Zentralschweiz, Luzern
    Lucerne, 6000, Switzerland
    Recruiting
  • Ostschweizer Kinderspital
    Sankt Gallen, 9006, Switzerland
    Recruiting
  • Universitäts-Kinderspital Zürich
    Zurich, 8091, Switzerland
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Nov 2038, 180 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Jan 14, 2022
StartActual
Nov 2, 2023
Primary completionEst.
Nov 2, 2038
CompletionEst.
Nov 2, 2038
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05192980
Lead sponsor
Institut Curie
Responsible party
Sponsor
First posted
Jan 14, 2022
Start date
Nov 2, 2023
Primary completion
Nov 2, 2038 (estimated)
Completion
Nov 2, 2038 (estimated)
Last update
Jul 22, 2025

Study contacts

Gudrun Schleiermacher, MD,PhD
Contact
gudrun.schleiermacher@curie.fr
0144324554
Kamel BOURZAH, MD
Contact
kamel.bourzah@curie.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion